NEW YORK, Oct. 9, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the closing of a previously announced underwritten public offering of 5,750,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 750,000 shares, offered at a price to the public of $7.00 per share. The gross proceeds to the Company were $40,250,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
NeoStem Announces Closing Of Public Offering Of Common Stock
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.